TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36227421

Group type: EXPERIMENTAL
Intervention: Ropivacaine group (group N, 0.375% ropivacaine 40 ml + normal saline 4 ml)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate group (group M, 0.375% ropivacaine 40 ml + 10% magnesium sulfate 4 ml)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (group C, normal saline 44 ml)
Number of subjects: 90
Study: 33472301

Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Betahistine (12 mg orally three times a day for four weeks)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (no specific treatment)
Number of subjects: 129
Study: 32499125

Group type: EXPERIMENTAL
Intervention: Acupuncture (18 sessions over 6 weeks)
Number of subjects: 519

Group type: COMPARATOR
Intervention: PEG 4000 (20 g/d for IBS-C) / Pinaverium bromide (150 mg/d for IBS-D)
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Between-group comparison
Number of subjects: 519
Study: 35241246

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 6263

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 6263
Study: 36333810

Group type: EXPERIMENTAL
Intervention: Multicomponent training (Multi)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Multicomponent training + self-management strategies (Multi+SM)
Number of subjects: 80
Study: 34116873

Group type: EXPERIMENTAL
Intervention: 3-antigen hepatitis B vaccine (3A-HBV) lot A
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: 3-antigen hepatitis B vaccine (3A-HBV) lot B
Number of subjects: 267

Group type: COMPARATOR
Intervention: 1-antigen hepatitis B vaccine (1A-HBV) Engerix-B
Number of subjects: 267
Study: 36028413

Group type: EXPERIMENTAL
Intervention: Family‐Centered Empowerment Model (FCEM)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 50
Study: 32193758

Group type: EXPERIMENTAL
Intervention: Deep belief network model using Macc 166 bit features
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deep belief network model using PubChem 881 bit features
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deep belief network model using Morgan 2048 bit features
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model performance with external data from drug banks and ZINC database
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Misclassified non-drug small molecules
Number of subjects: 0
Study: 32803003

Group type: EXPERIMENTAL
Intervention: Knowledge of country-specific public recommendations regarding vaccinations
Number of subjects: 3652

Group type: EXPERIMENTAL
Intervention: Knowledge about vaccinations against measles, influenza, and HPV
Number of subjects: 3652

Group type: EXPERIMENTAL
Intervention: Attitudes concerning vaccinations in general and for healthcare workers (HCWs)
Number of subjects: 3652
Study: 34648948

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 0
Study: 33482247

Group type: EXPERIMENTAL
Intervention: Imatinib, 400 mg daily for 2 years
Number of subjects: 908

Group type: COMPARATOR
Intervention: No further therapy after surgery
Number of subjects: 908
Study: 33727409

Group type: EXPERIMENTAL
Intervention: Early antihypertensive treatment, aimed at average systolic BP reduction by 10%-20% within the first 24 hours and achieving BP <140/90 mm Hg within 5 days.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed antihypertensive treatment, no antihypertensive medications for the first 7 days, then achieving BP <140/90 mm Hg after 7 days.
Number of subjects: 0
Study: 32851636

Group type: EXPERIMENTAL
Intervention: Caffeine (6.5 mg·kg‐1 body mass)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Carbohydrate (6 g of maltodextrin rinsed for 10 s)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Caffeine plus carbohydrate
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 36173609

Group type: EXPERIMENTAL
Intervention: Doxycycline (50 mg once daily for 12 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (once daily for 12 weeks)
Number of subjects: 100
Study: 33550634

Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Q-switched neodymium-doped yttrium aluminum garnet laser (QS)
Number of subjects: 22
Study: 36158665

Group type: EXPERIMENTAL
Intervention: Intravenous paclitaxel 135 mg/m2 plus mFOLFOX6
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intraperitoneal paclitaxel 80 mg/m2 plus mFOLFOX6
Number of subjects: 90

Group type: COMPARATOR
Intervention: mFOLFOX6
Number of subjects: 90
Study: 33814441

Group type: EXPERIMENTAL
Intervention: Probiotic Bifidobacterium breve MCC1274
Number of subjects: 0
Study: 35037057

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Mediterranean/low-carbohydrate diet
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Added physical activity
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: No added physical activity
Number of subjects: 220

Group type: COMPARATOR
Intervention: Overall association
Number of subjects: 220

Group type: COMPARATOR
Intervention: Interaction with baseline fasting plasma glucose
Number of subjects: 220
Study: 33077155

Group type: EXPERIMENTAL
Intervention: Preoperative axillary ultrasound (AUS)
Number of subjects: 462
Study: 34717672

Group type: EXPERIMENTAL
Intervention: Moving condition (congruent moving virtual hand)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Static condition (static virtual hand)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hidden condition (no virtual hand)
Number of subjects: 20
Study: 35280907

Group type: EXPERIMENTAL
Intervention: Sarilumab (single 400 mg dose in two 200 mg subcutaneous injections)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sarilumab
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sarilumab and Standard care
Number of subjects: 30
Study: 33164259

Group type: EXPERIMENTAL
Intervention: Clonidine or spironolactone (fourth drug)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Serum asymmetric dimethylarginine (ADMA)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Treatment with antihypertensive drugs (first phase V0-V3)
Number of subjects: 103
Study: 36400418

Group type: EXPERIMENTAL
Intervention: ANT14 (14 days of antofloxacin-based bismuth quadruple therapy)
Number of subjects: 1174

Group type: EXPERIMENTAL
Intervention: ANT10 (10 days of antofloxacin-based bismuth quadruple therapy)
Number of subjects: 1174

Group type: COMPARATOR
Intervention: CLA14 (14 days of clarithromycin-based bismuth quadruple therapy)
Number of subjects: 1174

Group type: EXPERIMENTAL
Intervention: ANT10 and ANT14
Number of subjects: 1174
Study: 33954933

Group type: EXPERIMENTAL
Intervention: Oral abrocitinib 200 mg
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: Oral abrocitinib 100 mg
Number of subjects: 942

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 942
Study: 33594987

Group type: EXPERIMENTAL
Intervention: Dexcom G5 Mobile (DG5)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Eversense (EVS)
Number of subjects: 11
Study: 35397122

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: No preoperative chemotherapy
Number of subjects: 62
Study: 32365675

Group type: EXPERIMENTAL
Intervention: Low-dosed milk protein hydrolysate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34198250

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided EVT technique
Number of subjects: 479
Study: 33053626

Group type: EXPERIMENTAL
Intervention: EOD‐1PM
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 36419389

Group type: EXPERIMENTAL
Intervention: CALM intervention
Number of subjects: 90

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 90
Study: 33599841

Group type: EXPERIMENTAL
Intervention: De-escalation treatment options (cetuximab-based radiotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) protocols
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Toxicity reporting
Number of subjects: 0

Group type: COMPARATOR
Intervention: De-intensified strategies
Number of subjects: 0
Study: 33241599

Group type: EXPERIMENTAL
Intervention: Thulium laser enucleation of the prostate
Number of subjects: 140

Group type: COMPARATOR
Intervention: Bipolar transurethral resection of the prostate
Number of subjects: 140
Study: 34052121

Group type: EXPERIMENTAL
Intervention: Mindful breath awareness & muscle relaxation (MBMR)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Transcranial electrical stimulation (tCES)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mindful breath awareness & muscle relaxation + Transcranial electrical stimulation (MBMR+tCES)
Number of subjects: 30
Study: 33499531

Group type: EXPERIMENTAL
Intervention: iPad measurement of near point of convergence (NPC)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: iPad measurement of distance visual acuity
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Convergence Insufficiency Symptom Survey
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Reading fluency assessment using iPad
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: iPad measurement of NPC
Number of subjects: 50
Study: 35485512

Group type: EXPERIMENTAL
Intervention: Group 2 (propofol induction + sevoflurane/remifentanil maintenance)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Group 3 (propofol induction + desflurane/remifentanil maintenance)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Group 1 (pentothal induction + desflurane/remifentanil maintenance)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Group 4 (pentothal induction + sevoflurane/remifentanil maintenance)
Number of subjects: 100
Study: 33755110

Group type: EXPERIMENTAL
Intervention: PN-HPT (4.0 mL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (4.0 mL normal saline)
Number of subjects: 20
Study: 35232423

Group type: EXPERIMENTAL
Intervention: 30 mg oral Dydrogesterone daily
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 250 mg intramuscular 17α‐OHPC weekly
Number of subjects: 150

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 150
Study: 33946203

Group type: EXPERIMENTAL
Intervention: KEPT-app (Kegel Exercise Pregnancy Training app)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 64
Study: 35668036

Group type: EXPERIMENTAL
Intervention: Pare de Fumar Conosco
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study: 33818170

Group type: EXPERIMENTAL
Intervention: Tafluprost (15 mg/ml)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Bimatoprost (0.1 mg/ml)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Comparison of tafluprost and bimatoprost
Number of subjects: 64
Study: 32910712

Group type: EXPERIMENTAL
Intervention: Video-assisted education
Number of subjects: 140

Group type: COMPARATOR
Intervention: Traditional face-to-face discussion
Number of subjects: 140
Study: 35357881

Group type: EXPERIMENTAL
Intervention: Propranolol (β-blocker)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33706001

Group type: EXPERIMENTAL
Intervention: Native CHOICES intervention (2 motivational interviewing sessions, elective contraception counseling session, electronic messaging)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Services-as-usual, waitlist control condition
Number of subjects: 0
Study: 32122898

Group type: EXPERIMENTAL
Intervention: Intravenous dalbavancin at 1,500 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intraperitoneal dalbavancin at 1,500 mg
Number of subjects: 10
Study: 616803936

Group type: EXPERIMENTAL
Intervention: Preoperative education
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (no preoperative education)
Number of subjects: 130
Study: 35748757

Group type: EXPERIMENTAL
Intervention: Active group (external concurrent occipital and trigeminal neurostimulation)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 131
Study: 34468609

Group type: EXPERIMENTAL
Intervention: Vertical incision
Number of subjects: 61

Group type: COMPARATOR
Intervention: Transversal incision
Number of subjects: 61
Study: 33502291

Group type: EXPERIMENTAL
Intervention: Self-assessed moderate or severe asthma
Number of subjects: 1828

Group type: EXPERIMENTAL
Intervention: Age >60 years
Number of subjects: 1828

Group type: EXPERIMENTAL
Intervention: Allergic rhino-conjunctivitis
Number of subjects: 1828

Group type: EXPERIMENTAL
Intervention: Sinusitis
Number of subjects: 1828

Group type: EXPERIMENTAL
Intervention: Poor asthma control (ACT <20)
Number of subjects: 1828

Group type: EXPERIMENTAL
Intervention: Emergency care visits the previous year
Number of subjects: 1828

Group type: EXPERIMENTAL
Intervention: Lower level of education (women)
Number of subjects: 1828

Group type: EXPERIMENTAL
Intervention: Lower level of education (men)
Number of subjects: 1828
Study: 32318872

Group type: EXPERIMENTAL
Intervention: Multidisciplinary video consultations
Number of subjects: 100
Study: 34151818

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation Therapy (PMRT)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional physical therapies (non-PMRT group)
Number of subjects: 37
Study: 32106141

Group type: EXPERIMENTAL
Intervention: efavirenz (600 mg daily with NRTIs)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: atazanavir/ritonavir (300/100 mg daily with NRTIs)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (no antiretrovirals)
Number of subjects: 72
Study: 33657959

Group type: EXPERIMENTAL
Intervention: 80 mg nano-curcumin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 32328824

Group type: EXPERIMENTAL
Intervention: G‐POEM (Gastric peroral endoscopic myotomy)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Endoscopist experience with <20 G‐POEM procedures
Number of subjects: 216

Group type: COMPARATOR
Intervention: Endoscopist experience with >20 G‐POEM procedures
Number of subjects: 216
Study: 35854236

Group type: EXPERIMENTAL
Intervention: Toripalimab (240 mg) every 3 weeks during concurrent chemoradiotherapy and once every 6 weeks after consolidation chemotherapy for up to 1 year.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy with intensity modulated radiotherapy and high‐dose rate brachytherapy, along with weekly DDP (40 mg/m2) during radiotherapy and 6 cycles of consolidated chemotherapy (paclitaxel plus DDP) after radiotherapy.
Number of subjects: 0
Study: 33130851

Group type: EXPERIMENTAL
Intervention: Apolipoprotein B (ApoB)
Number of subjects: 24925
Study: 35666852

Group type: EXPERIMENTAL
Intervention: Budesonide oral suspension (BOS) low dose: 0.35 or 0.5 mg; high dose: 1.4 or 2.0 mg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Budesonide oral suspension (BOS)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 34027030

Group type: EXPERIMENTAL
Intervention: Atomoxetine (20 mg daily for two weeks followed by 40 mg daily for two weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Atomoxetine (in subgroup with systolic blood pressure < 110 mmHg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (in subgroup with systolic blood pressure < 110 mmHg)
Number of subjects: 46
Study: 32133907

Group type: EXPERIMENTAL
Intervention: PACT
Number of subjects: 38

Group type: COMPARATOR
Intervention: CBT
Number of subjects: 38
Study: 35045980

Group type: EXPERIMENTAL
Intervention: Gastrografin (100 mL oral dose)
Number of subjects: 20
Study: 33064487

Group type: EXPERIMENTAL
Intervention: Pyrene dimerization at various temperatures (600, 900, 1200, 1600, and 2000 K) with collisional impact parameters (0‐18 Å)
Number of subjects: 1000
Study: 34370975

Group type: EXPERIMENTAL
Intervention: Continuation of renin-angiotensin system inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Discontinuation of renin-angiotensin system inhibitors
Number of subjects: 0
Study: 32402681

Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy with bevacizumab (6 cycles of FOLFOX/FOLFIRI before and after surgery)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Postoperative chemotherapy with bevacizumab (12 cycles after surgery)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy with bevacizumab (in subgroup with CEA ≥ 5 ng/mL)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy with bevacizumab (in subgroup with over 2 liver metastases)
Number of subjects: 76
Study: 32468087

Group type: EXPERIMENTAL
Intervention: Nangibotide (0.3, 1.0, or 3.0 mg/kg/h)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Nangibotide
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 36104719

Group type: EXPERIMENTAL
Intervention: MRV-MNP and placebo (0.9% sodium chloride) subcutaneous injection
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo MNP and MRV by subcutaneous injection (MRV-SC)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: MRV-MNP
Number of subjects: 285

Group type: COMPARATOR
Intervention: MRV-SC
Number of subjects: 285
Study: 33705543

Group type: EXPERIMENTAL
Intervention: Lifestyle or metformin interventions
Number of subjects: 1876

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1876

Group type: EXPERIMENTAL
Intervention: Participants with diabetes
Number of subjects: 1876

Group type: EXPERIMENTAL
Intervention: Participants without diabetes
Number of subjects: 1876
Study: 32028783

Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 42
Study: 35767567

Group type: EXPERIMENTAL
Intervention: Reverse homology approach using contrastive learning for IDRs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reverse homology approach
Number of subjects: 0
Study: 32060605

Group type: EXPERIMENTAL
Intervention: LOPOSAM technique
Number of subjects: 22

Group type: COMPARATOR
Intervention: Rubin JP technique
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 22
Study: 34118609

Group type: EXPERIMENTAL
Intervention: High-dose oral pyridoxine (100-300 mg/kg/day) in combination with ACTH (150 IU/m2/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard ACTH therapy alone
Number of subjects: 80
Study: 35235659

Group type: COMPARATOR
Intervention: Placebo (PCB)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Exenatide (EXE), 5 μg s.c.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (DAPA), 10 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: DAPA/EXE
Number of subjects: 48
Study: 35835685

Group type: EXPERIMENTAL
Intervention: Acupressure (36 min, three times weekly for one month)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Observation (one month)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Acupressure (after observation)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Observation (before acupressure)
Number of subjects: 23
Study: 32800438

Group type: EXPERIMENTAL
Intervention: Bikini incision
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional longitudinal incision (control)
Number of subjects: 0
Study: 33957098

Group type: EXPERIMENTAL
Intervention: High construal/promotion focus advertisement
Number of subjects: 191

Group type: COMPARATOR
Intervention: Low construal/prevention focus advertisement
Number of subjects: 191
Study: 33027644

Group type: EXPERIMENTAL
Intervention: Mineralocorticoid receptor antagonists (MRA)
Number of subjects: 0
Study: 33620714

Group type: EXPERIMENTAL
Intervention: Patient navigation + behavioral incentives (PNBI)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Assessment + standard care (ASC)
Number of subjects: 150
Study: 34693933

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) based ART
Number of subjects: 52

Group type: COMPARATOR
Intervention: Nonnucleoside reverse transcriptase inhibitor (nNRTI) based ART
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Time-to-clearance
Number of subjects: 52
Study: 33966435

Group type: EXPERIMENTAL
Intervention: Ripretinib
Number of subjects: 1
Study: 33567423

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (800 mg + 5 μg Vitamin D)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Sodium bicarbonate (1,000 mg)
Number of subjects: 55
Study: 32343193

Group type: EXPERIMENTAL
Intervention: Targeted electronic outreach
Number of subjects: 114

Group type: COMPARATOR
Intervention: Banner ads on social media
Number of subjects: 114
Study: 32330183

Group type: EXPERIMENTAL
Intervention: Food pictures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-food pictures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Food pictures followed by milkshake
Number of subjects: 0
Study: 32744441

Group type: EXPERIMENTAL
Intervention: Increasing basal heart rate (BHR) categorized into <60 bpm, 60-89 bpm, and ≥90 bpm.
Number of subjects: 1349

Group type: EXPERIMENTAL
Intervention: Mean diastolic blood pressure
Number of subjects: 1349

Group type: EXPERIMENTAL
Intervention: Fasting blood glucose
Number of subjects: 1349
Study: 32847991

Group type: EXPERIMENTAL
Intervention: Occupational exposures (22 agents)
Number of subjects: 882

Group type: COMPARATOR
Intervention: Control group (521 women without lung cancer)
Number of subjects: 882
Study: 33280953

Group type: EXPERIMENTAL
Intervention: High intensity resistance training (RTG)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham resistance training (CG)
Number of subjects: 48
Study: 33798731

Group type: EXPERIMENTAL
Intervention: PATH intervention (online portal and twice a month phone calls from a PA coach)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Attention control group (self-help PA handout and twice a month general health newsletter)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PATH intervention
Number of subjects: 30
Study: 35954922

Group type: EXPERIMENTAL
Intervention: Digital physiotherapy intervention (4-week duration, individualized and customized exercise program)
Number of subjects: 32